Bionano Genomics Inc BNGO

$1.25 -0.12 (-8.76%)

Valuation

Market cap
14,721,000
Revenue TTM
$28,510,000
Net income TTM
$-26,400,000
PE ratio
0.00
Forward PE
—
Profit margin
-92.60%
Debt to equity
0.00

Trading

Volume
181,100
Avg volume
1,161,462
Day's range
$1.25 – $1.39
Shares out
11,777,000
Stochastic %K
0%
Beta
1.66
Analysts
Strong Sell
Price target
$5.00

Price

Company profile

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal...

Show more

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Industry
Medical Instruments & Supplies
Sector
Healthcare
Phone
858 888 7600
Website
https://bionano.com
Address
9540 Towne Centre Drive, Suite 100, San Diego, United States

Latest news

Stocktwits

JinUzuki Oct 18, 1:02 PM 0 replies
mclovin5 Oct 18, 12:13 PM
$BNGO Still here
0 replies
JumpStarting Oct 16, 8:08 PM
$FLNA $BNGO $TLRY Holding tight. When a hurricane rolls in, everything gets rattled. Nasdaq is down 2.14% as I write this. No panic—just riding out the storm. 🌪️
0 replies
JinUzuki Oct 16, 8:04 PM 0 replies
TheBioPunkRevenger Oct 16, 2:52 PM
$BNGO AmpliconReconstructorOM integrates Bionano optical maps with NGS breakpoint graphs to reconstruct complex focal amplifications (ecDNA, breakage-fusion-bridge, chromothripsis-related structures). Published in Nature Communications. Takes Bionano CMAP assemblies + AmpliconArchitect output and scaffolds the large-scale architecture that short-read alone cannot resolve cleanly. This is the research ecosystem building on optical mapping data for cancer structural variants. OGM images the native ultra-long molecules; tools like this turn those maps into usable reconstructions of the hard cases. 81195 live. MolDX heme draft out. Q2 chips +27%. Installed base running. They’re still pricing a single kit. The map and the tools around it keep expanding the menu. https://github.com/AmpliconSuite
0 replies
KellyHanzee Oct 14, 3:14 PM
$BNGO where’s Cathy Wood?
0 replies
TheBioPunkRevenger Oct 13, 5:37 PM
$BNGO ACLA (American Clinical Laboratory Association) backed finalization of the MolDX genome-wide CNA/SV LCD for hematologic neoplasms. They flag OGM as a single-assay method that captures CNAs and SVs genome-wide — better than karyotype + multi-FISH + microarray. Major clinical lab trade group supporting the pathway. MolDX advises MACs covering ~61% of U.S. Medicare. Finalization + TA would open 81195 ($1,853.22) for OGM in heme across that footprint. One policy lever expands paid volume. More covered lives = more labs = more flow cells. Q2 +27% chips. NYSDOH LDTs live. MSK on heme OGM. Street still prices a ~$15–20M distressed kit. Broader Medicare coverage is the volume multiplier the model ignores. 15σ financial detachment continues.
1 replies
TheBioPunkRevenger Oct 13, 5:21 PM
$BNGO EA4HP (European Association for Haematopathology) webinar 28 Oct: “Improving structural variant detection in lymphoma using Optical Genome Mapping (OGM).” Speakers from Hospital Clínic Barcelona, CHU Liège, Cochin/Cordeliers. Professional society education on OGM for lymphoma SVs — space with published NHL data showing high concordance, karyotype rescue, and extra clinical events. Lymphoma is heme. Live 81195 @ $1,853.22. European groups already issuing OGM implementation statements. Another signal the tech is moving into routine clinical discussion. Kit model still priced. Menu keeps getting visibility. 15σ continues. https://www.european-association-for-haematopathology.org/product/ea4hp-webinar-improving-structural-variant-detection-in-lymphoma-using-optical-genome-mapping-ogm-28-october-2026-at-0500-pm-cet/
0 replies